Rapt Therapeutics
Founded 2015 · CIK 0001673772 · Biotech · Acquired
Oral small molecule CCR4 antagonist
rapttx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $303M
- 5 Form D · Jan 2025
- 21 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 12 granted · 28 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $50,000,000 | |
| Private capital raised | Form D · SEC | $29,927,851 | |
| Private capital raised | Form D · SEC | $22,634,798 | |
| Private capital raised | Form D · SEC | $50,000,000 | |
| Private capital raised | Form D · SEC | $149,984,200 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1634 | MANHATTAN BIOSOLUTIONS, LLC | — | — |
| 1635 | Find Genomics Inc. | — | — |
| 1636 | Amplifier Therapeutics | — | — |
| 1637 | Rapt Therapeutics | — | $303M |
| 1638 | SAPPHIRE BIOTECH, INC. | — | — |
| 1639 | Atalanta Therapeutics | — | — |
| 1640 | Aera Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Dirk BrockstedtExecutive Officer
- Michael GiordanoDirector
- David GoeddelDirector
- Mary Ann GrayDirector
- Eric HallExecutive Officer
- Rekha HemrajaniExecutive Officer
- William HoExecutive Officer
- Paul KassnerExecutive Officer
- Linda KozickDirector
- Tim LinExecutive Officer
- Lori Lyons-WilliamsDirector
- William RieflinDirector
- Wendye RobbinsDirector
- Beth SeidenbergDirector
- Brian WongDirector · Executive Officer
- David WustrowExecutive Officer
- Rodney YoungExecutive Officer
Patents
- Chemokine Receptor Modulators And Uses Thereofapplication
- Methods Of Making Trans Isomeric Forms Of G Protein-coupled Receptor Modulatorsapplication
- Chemokine Receptor Modulators And Uses Thereofapplication
- Methods Of Making Trans Isomeric Forms Of G Protein-coupled Receptor Modulatorsgranted
- Chemokine Receptor Modulators And Uses Thereofapplication
- Chemokine Receptor Modulators And Uses Thereofgranted
- Chemokine Receptor Modulators And Uses Thereofapplication
- Crystalline Forms Of C-c Chemokine Receptor Type 4 Antagonist And Uses Thereofapplication
- Crystalline Forms Of C-c Chemokine Receptor Type 4 Antagonist And Uses Thereofapplication
- Chemokine Receptor Modulators And Uses Thereofgranted
- Chemokine Receptor Modulators And Uses Thereofapplication
- Crystalline Forms Of C-c Chemokine Receptor Type 4 Antagonist And Uses Thereofgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.